Observe Medical ASA: Notice of extraordinary general meeting on 17 July 2024 in connection with the private placement and a contemplated subsequent offering
Oslo, 26 June 2024
Reference is made to the stock exchange announcement by Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) on 24 June 2024, regarding the successfully placed private placement of new shares in the Company to raise gross proceeds of NOK 22 million (the "Private Placement").
In connection with completion of the Private Placement and a contemplated subsequent offering, the Company hereby calls for an extraordinary general meeting to be held on 17 July 2024 at 14:00 hours (CEST). The extraordinary general meeting will be held as a physical meeting, at Haakon VIIs gate 1, 7th floor at Reiten & CO, 0161 Oslo, Norway.
The notice of the extraordinary general meeting is attached, together with the attendance and proxy forms. The notice has been sent to shareholders with known addresses, and is also available on the Company's website www.observemedical.com.
For further information, please contact:
Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: [email protected]
Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: [email protected]
About Observe Medical:
Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.
The Company seeks to drive growth by leveraging its expertise in sales and commercialisation of its broad portfolio of medical technology products, mainly in urine measurement and ultrasound, in combination with targeted M&A and distribution. Observe Medical is working with a network of leading distributors to provide outstanding solutions for healthcare professionals globally.
The Company is headquartered in Oslo, Norway.
Further information is available at www.observemedical.com.
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
